Albireo Announces Positive Results from a Study with A3309 in Patients with Chronic Constipation
“The results show that A3309 was found to be safe and well tolerated and identified clear signs of improving colonic motility and bowel habits”, said Magnus Simrén, Principal Investigator (Institute of Medicine, Sahlgrenska Academy, University of Gothenburg , Sweden).
“We are excited about the results of the trial which confirms the potential that A3309 will benefit all those patients suffering from constipation and abdominal pain/discomfort who are refractory to OTC drugs.” said Hans Graffner, Chief Medical Officer at Albireo. “The Albireo team looks forward to advancing the development of A3309, a first-in-class compound with a novel mode of action, and to create a new tool in the therapeutic armamentarium for these patients with limited treatment options.”
A3309 is currently being evaluated in a large Phase IIb study in chronic constipation enrolling approximately 180 patients in the US and further investigation of A3309’s enhancement of large bowel transit is being conducted at the Mayo Clinic. Also, given the mode of action, A3309 may be beneficial in patients with dyslipidemia and a study to evaluate A3309 in patients with high cholesterol levels is conducted in Sweden. Results of these clinical studies will be available late this year and plans are to move forward into Phase III in chronic constipation during 2011.
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.